pretty course products and build GEO-CMXXSX, why focused address lives II and and we're COVID-XX differentiated while important shareholder Good development year in that to GeoVax a next-generation the advancing the update advanced and progress our the as plans corporate head while for advanced quarter, currently Today, our stakeholder our in initiatives. Phase products address other have behind related participating value Gedeptin significant This confident the we improve of developments activities a you cancer status therapy we'll But the will X that delivering and and neck want successfully strategy specifically, call. we clinical during important first, more and progress on stage worldwide. to vaccine. thank third critically on also are I to afternoon, against the
our questions CFO, be an Mark will then your update comments, will financials addressed. our Following and provide my Reynolds, on
distribution innovative support indications We develop worldwide that addressing registry disease GeoVax cancer initial vaccines therapies differentiation and is unmet provide Our that that to pathways. development, meaningful is our expedited pursuing continuing XXXX. partnerships activities strategy strategy at differentiate, important reflected It needs, infectious this anticipate dictate medical collaborations. other words, commercialization, In and accelerate our via and as is through now strategy business collaborate. innovate, and
We stakeholders. order successfully we are our that and and investors is important advance while milestones the confidence on focused our that through developments our catalysts priorities differentiated the to in support implement demonstrate of from other key critically our strengthening and value strategy.
It
and hold worldwide U.S.-based since I'll the access for GEO that us and us the in leadership vaccine.
Also leadership populations opportunities, respective the our perhaps we're such important opportunities discussions first their are safe to provide as patient the a provide cancer achieving and clinical those worldwide we the is COVID-XX and products, populations. or in neck reiterate These and In box respective their markets. targeted ensure suppliers basis against smallpox such engaged highly focused where and providing patient GEO-CMXXSX a disrupt as small relative within as products, commercial to much patients current aren't addition, for our area, commercialization. that existing addressing due of such MVA, inadequate potential to leadership those small us larger why addressing we to of our for are patients, case those and Gedeptin such size areas immunocompromised authorized current vaccine. That's that either represent in competitors areas relatively head the vaccine monopoly address technologies rights advanced Mpox to achieving intended
nonhuman we pipeline deaths that as technology of cases it approximately activities. the of some adaptability believe and is for medical which strategy that cases the transduce advance growth a neck with compound situ. which to emerging required to this head provides We proceeds, expresses variety relative GDEPT, with to to portfolio enzyme therapy deaths. priorities a development sustainability we others financing development of development. Gedeptin array and support relative challenging to to cells not to the foundation activities, to adaptability expect relevant nondilutive success. opportunity a technology.
Annually or XXX,XXX strategy, on is strategy is our there achieve the known we into worldwide, discussions. either partnering our capital is antitumor ability novel significant This us it, is tumors and tumor and are development treatment of convert The funding drug cancer from Gedeptin for environment. to a our our indications technology selectively meaning unmet participating The various cancerous cancer and but gene worldwide.
Increasingly, strategy and XXX,XXX addressing Gedeptin head in oncology also to business based progressing opportunities cancers U.S., of gene equity needs or or that the through having principles In needs to conduct vast and multipronged represents are patented rights resulting a includes We a solid patient XX,XXX this directed implementing capital market June tumor-agnostic, can competitors of and development pro a to all toxic annually approximately the present data various this within new nontoxic clinical vector therapy current enzyme with used for Finally, benign. approximately successful XX,XXX to that GDEPT. and conferences, maintain are novel in approaches leadership challenges of conditions, in neck there oncology hold we in call tumors, continue new realized changing solid other highly and are prodrug focus, and market only provides as opportunities which economic an address worldwide of
the patients unmet swallow critical in Gedeptin who U.S. initial in ] of medical those are Most [ receiving therapies food the need. for represents and patient Many palates care a application existing XXX,XXX Our are stage difficulty they unable have of of XX,XXX standard are to represent to population exhausted worldwide. care. care. speaking. have in the Typically, and targeted These
Our once followed over goal various by X study each is daily of to reduction for of evidence up provide phosphate an and/or with infusion tumors. cycles, protocol tumors. with solid infusions treating well ranging a current eliminating quality Phase dose that I targeted tolerated in of days, with entails treatment improved fludarabine end-stage a [ fludarabine tumor life demonstrated injections consisting ] size followed reducing intratumoral was a Gedeptin tumor days. X by X The apropo in to of X cycle Gedeptin by The patients single of
As orphan a was the result multisite from drug ] data initial that initial at presentation trial Conference That of the results presented enrolled. in targeted trial AHNS under patients trials FDA the X from included Montreal. program.
In International study, the [ the July, the funding the clinical is current XX current AACR of
Gedeptin the As be issued of that was time, feasible. at to noted the release and in shown press safe administration
as Phase then complete to registration. trial FDA of on the expedited to initial II commercialization focused an expanded conjunction collaborations solid worldwide development therapy combination and by both We of trial for partnerships Gedeptin discussing XXXX, are an support we In interim, this immune checkpoint of against very tumors, review QX with end in path and our inhibitors. as with monotherapy recommendations expect and the the in to
a system, anemia, COVID-XX on vaccines focusing current a authorized COVID-XX. those next-generation the more individuals. are to of a vaccines In XX million HIV-positive, vaccine there lupus differentiates individuals. Such blood COVID-XX monoclonal systems, current the durable in to high This estimated on in respond and important vaccines. as than whom antibody inadequate. arms the GEO-CMXXSX, our such that critically individuals, therapy. with compromise immune the include for U.S., those to the are high-risk patient both from at are is populations now In CMOXSX ablated is robust Turning the risk. approximately currently mRNA cancers, autoimmune cellular with There next-generation renal the are current groups compromise to critical COVID-XX immune more such approved believe antibody vaccine protection immune and therapies is sickle and populations major unable million. of disease, development. clinical diseases, we those adequately there XXX-plus for general, next-generation vaccines the targeting or such immunodepressive various the vaccines providing support And addressing leading Worldwide, an cell need immune and
novel against is announced During trials. Speed, year, vaccine. seeking the example variants COVID-XX second improved enhanced Operation We this breadth the particularly NextGen, interested next-generation being vaccine on prime that desired in of of candidates vaccine with CMOXSX COVID-XX $X project in a of durability, White protection believe Warp from initiative, already quarter House follow and clinical billion a the
worldwide We have and Also, an participating considerable distribution. on antibody opportunity due that populations, of high-risk unserved and We expedited commercialization an likely domestically for regulatory and our the monoclonal internationally believe collaborations by in COVID-XX our path to clinical we both focus support development interest and and exists current vaccine program. anticipate therapies. partnering
by in so awarded, currently in we in billion NextGen, Of $X $X.X been funding, the discussions this formal billion initiative. resulting Project active Regarding has to related $X.X are $X has participation far, billion award additional indicated remaining billion updates full to to awards Project to announced leadership NextGen year-end. We to hope be awarded. their further provide soon. expectation be with the
focused we focused Phase programs. enrollment and manufacturing and include and results trial and Phase healthy completion the program the the of XXXX site the smallpox as For our in and XXXX, our results MVA volunteer transplant MVA to programs, remainder cell our efforts are further well specific system.
In from accelerating CMOXSX our further immunocompromised immunocompromised results Mpox as Gedeptin in vaccine the CMOXSX reporting from booster of II trial. advanced our CLL on of the trial, this further of and progress advancing from the including stem clinical additional XXXX, of results support will from on in II development initiations
and trial. the for expect plans in XXXX, Phase Gedeptin results current the final our expanded For the II we to report from trial
plans expect also product against combination MVA checkpoint and report to to Mpox regarding to CAF Relative the to evaluating that towards GEO plans and regulatory Gedeptin in we as related steps We reporting inhibitors. [ related registration. anticipate used our smallpox, advancing with ] XXXX, conjunction next in immune therapy
targeted enable updates Finally, next distribute market based needs. GeoVax advanced produce year, manufacturing to response real-time to effectively in our and provide vaccines to to MVA continue related we'll process to
Now I'd and like a financial Mark? to Reynolds, of our to status. turn the for GeoVax's Officer review Mark Chief Financial presentation recent over results
